PF-08052667

Antibody–drug conjugate

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Non-Muscle Invasive Bladder Cancer
NCT07206225 · Pfizer
2025-11-06 – 2033-01-28 · Non-muscle Invasive Bladder Cancer
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
PF-08052667: this drugPhase 1Antibody–drug conjugateIntegrin beta-6 (ITGB6)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SHR-1501Phase 3UndisclosedIL-15not yet gradedNo reviewed efficacy summary in this indication
Sigvotatug Vedotin
Phase 3(overall)
Antibody–drug conjugateIntegrin beta-6 (ITGB6)
not yet graded(overall)
No reviewed efficacy summary in this indication
TAR-210Phase 3Intravesical Drug Delivery System (erdafitinib)—not yet gradedNo reviewed efficacy summary in this indication
TARA-002Phase 3Bacterial immunotherapyInnate and adaptive immune activation (inactivated Streptococcus pyogenes)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow PF-08052667 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
January 2030 (1)
Phase 1Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2030-01-29 · NCT07206225 · CT.gov ↗
What to watch

See the full readout calendar ↗